SML3959
VS-5584
≥98% (HPLC)
Synonym(s):
5-(9-Isopropyl-8-methyl-2-morpholin-4-yl-9H-purin-6-yl)-pyrimidin-2-ylamine, 5-[8-Methyl-9-(1-methylethyl)-2-(4-morpholinyl)-9H-purin-6-yl]-2-pyrimidinamine, SB 2343, SB-2343, SB2343, VS 5584, VS5584
Sign In to View Organizational & Contract Pricing.
Select a Size
About This Item
Empirical Formula (Hill Notation):
C17H22N8O
CAS Number:
Molecular Weight:
354.41
UNSPSC Code:
12352200
NACRES:
NA.77
MDL number:
SMILES string
N4(CCOCC4)c1nc2[n](c(nc2c(n1)c3cnc(nc3)N)C)C(C)C
InChI key
QYBGBLQCOOISAR-UHFFFAOYSA-N
assay
≥98% (HPLC)
form
powder
color
white to beige
solubility
DMSO: 2 mg/mL, clear
storage temp.
-10 to -25°C
Quality Level
Related Categories
Biochem/physiol Actions
Orally active, potent and highly selective mTOR and class I phosphoinositide 3-kinases (PI 3-kinases; PI3K) inhibitor with anti-cancer efficacy in vitro and in vivo.
VS-5584 (SB2343) is an orally active, potent and highly selective mTOR (IC50 = 37 nM) and class I phosphoinositide 3-kinases (PI 3-kinases; PI3K IC50 = 16 nM/α, 68 nM/β, 25 nM/γ, 42 nM/δ; little activity toward 400 other lipid and protein kinases) inhibitor with broad-spectrum anti-proliferation activity in cancer cultures (IC50 post 48h treatment from 48 nM to 1.75 μM among 50 cancer lines) by inhibiting PI3K and mTOR downstream substrates phosphorylation. VS-5584 displays tumor growth inhibition efficacy in various rapalog-sensitive and -resistant human xenograft models in mice in vivo (PC3 TGI = 79% and 113%, respectively, post 28-day 11 mg/kg or 25 mg/kg daily p.o. treatment).
VS-5584 (SB2343) is an orally active, potent and highly selective mTOR (IC50 = 37 nM) and class I phosphoinositide 3-kinases (PI 3-kinases; PI3K IC50 = 16 nM/α, 68 nM/β, 25 nM/γ, 42 nM/δ; little activity toward 400 other lipid and protein kinases) inhibitor with broad-spectrum anti-proliferation activity in cancer cultures (IC50 post 48h treatment from 48 nM to 1.75 μM among 50 cancer lines) by inhibiting PI3K and mTOR downstream substrates phosphorylation. VS-5584 displays tumor growth inhibition efficacy in various rapalog-sensitive and -resistant human xenograft models in mice in vivo (PC3 TGI = 79% and 113%, respectively, post 28-day 11 mg/kg or 25 mg/kg daily p.o. treatment).
Storage Class
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Regulatory Information
新产品
This item has
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Structure and ligand-based design of mTOR and PI3-kinase inhibitors leading to the clinical candidates VS-5584 (SB2343) and SB2602
Journal of Chemical Information and Modeling, 54(11), 3238-3250 (2014)
PI3K/mTOR dual inhibitor VS-5584 preferentially targets cancer stem cells
Cancer Research, 75(2), 446-455 (2015)
Stefan Hart et al.
Molecular cancer therapeutics, 12(2), 151-161 (2012-12-29)
Dysregulation of the PI3K/mTOR pathway, either through amplifications, deletions, or as a direct result of mutations, has been closely linked to the development and progression of a wide range of cancers. Moreover, this pathway activation is a poor prognostic marker
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service